CTOs on the Move

El Paso Orthopaedic Surgery Group

www.eposg.com

 
El Paso Orthopaedic Surgery Group is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in El Paso, TX. To find more information about El Paso Orthopaedic Surgery Group, please visit www.eposg.com
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million
  • www.eposg.com
  • 1720 Murchison Dr
    El Paso, TX USA 79902-2921
  • Phone: 915.533.7465

Executives

Name Title Contact Details

Similar Companies

Meta Pharmaceutical Services

Meta Pharmaceutical Services is a Blue Bell, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Monitor Medical Inc

Monitor Medical Inc is a Stafford, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hollenbeck Home

Serving the Greater Los Angeles area for more than a century, men and women in their senior years have enjoyed Hollenbeck`s vibrant, rewarding and comfortable environment, where friendships grow as personal interests are pursued. Hollenbeck Palms offers independent residential living, assisted residential living and skilled nursing services. Please refer to the main menu to view each of these opportunities for aging-in-place. Give us a call to schedule a convenient time to visit and enjoy an escorted tour of our impressive facilities and a complimentary lunch in our Grand Dining Room.

INFOHEALTH Management

INFOHEALTH Management Corp. is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.